Preliminary results of intra-artery chemotherapy for T1G3 bladder cancer
10.3969/j.issn.1006-5725.2015.20.030
- VernacularTitle:动脉化疗治疗T1G3膀胱癌疗效分析
- Author:
Yunlin YE
;
Zhuowei LIU
;
Fangjian ZHOU
;
Lijuan JIANG
;
Siliang CHEN
;
Qiuming HE
;
Zike QIN
- Publication Type:Journal Article
- Keywords:
bladder cancer;
Intra-artery chemotherapy;
T1G3
- From:
The Journal of Practical Medicine
2015;(20):3379-3381
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the outcome of intra-artery chemotherapy for T1G3 bladder cancer , and its effectiveness and safety. Methods From June 2003 to May 2014, 39 patients with T1G3 bladder cancer chose intra-artery chemotherapy (Gemcitabine plus cis-platin), and close follow-up was required after 2 cycles of chemotherapy. During the follow-up, transurethral resection of bladder tumor was performed for non-muscle invasive bladder cancer, and cystectomy was performed for muscle invasive tumor. Results Of all patients, 32 were male and 7 were female. The median age was 56 years old (range: 32-82 years), and median follow-up time was 56 months (range: 12-136 months). Nineteen patients were primary bladder cancer, and 20 were recurrent tumor. During the follow-up, 17 patients developed recurrent tumors, including 8 progressed tumors and 3 died from tumor. Two-year and 5-year progressed-free survival were 88% and 74%, and 2-year and 5-year cancer-specific survival were 97% and 89%, respectively. During 5 years′ follow-up, 81% survivor preserved intact bladder, and only 1 patient cancelled chemotherapy for adverse effect. Conclusions Intra-artery chemotherapy (GC regimen) is a choice for T1G3bladder cancer, preventing from disease progression with good tolerance.
